A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy

Stopped No safety signals were noted. The study was stopped because it was no longer consistent with the company's scientific and strategic focus.

Conditions

• Neoplasms
• Anemia
• Cancer

Interventions

• DRUG: epoetin alfa
• DRUG: darbepoetin alfa

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Collaborators

• [object Object]